A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)

NCT07227402 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

904

Enrollment

INDUSTRY

Sponsor class

Conditions

Renal Cell Carcinoma

Interventions

DRUG: Belzutifan
DRUG: Zanzalintinib
DRUG: Cabozantinib

Sponsor

Merck Sharp & Dohme LLC

Collaborators

[object Object]